- Location
Boehringer
"-
Association Welcomes Producers to Celebrate 60 Years at 2014 Missouri Pork Expo
Feb 10, 2014Columbia, Mo.,---- The Missouri Pork Association welcomes producers, suppliers and distributors to the 2014 Missouri Pork Expo to help us celebrate 60 years. The two-day event promotes the pork industry, educates youth and adults, and ...
Tags: pork
-
EDS Begun Testing for ERAV Using PCR Testing Method
Jan 17, 2014Lexington, Ky.-based Equine Diagnostic Solutions (EDS) has begun testing for equine rhinitis A virus (ERAV) using a polymerase chain reaction (PCR) testing method. EDS is now one of four labs in the United States offering this test, along ...
Tags: Agriculture, Food
-
Actavis Plc Has Received Approval From The U.S. FDA on ANDA
Jan 10, 2014Actavis plc (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a ...
-
BIVI Encourages Individuals Interested in Submitting PRRS Research Award Proposals to Do
Dec 27, 2013With porcine reproductive and respiratory syndrome (PRRS) costing U.S. swine producers more than $664 million annually in lost production, collaborative scientific research continues to be the industry's best hope for finding new ways to ...
Tags: Agriculture, Food
-
Veterans Bring 360o Insight to Developing Managed Market Solutions for Stakeholders
Dec 20, 2013Industry Veterans Bring 360o Insight to Developing Managed Market Solutions for Stakeholders HealthSTAR Communications, a leading healthcare communications company, today announced the formation of HEALTHSTAR Market Access, LLC, a ...
-
Boehringer Ingelheim Has Entered Into a Research Collaboration Agreement
Dec 20, 2013Boehringer Ingelheim has entered into a research collaboration agreement with and Circuit Therapeutics to discover new ways of treating psychiatric disorders. As per the deal, the companies will combine their research and development ...
Tags: Boehringer, Psychiatric Disorders
-
EMA Has Fully Validated and Granted Accelerated Assessment
Nov 28, 2013The European Medicines Agency (EMA) has fully validated and granted accelerated assessment to Boehringer Ingelheim's application for European marketing authorization of faldaprevir, a potent second generation oral protease inhibitor. ...
-
PHT Is Proud to Be a Part of This Project as The Ebook Represents Remarkable Collaboration
Nov 22, 2013Four scientists from top pharmaceutical companies have collaborated to bring together the successful strategies for implementing an electronic patient reported outcome (ePRO) system in the form of an ebook. The handbook named "How to ...
Tags: ePRO Strategy, PHT
-
Boehringer Ingelheim Has Submitted European Marketing Authorization Applications
Nov 15, 2013Boehringer Ingelheim has submitted European marketing authorization applications (MAA) to extend the indication to use tiotropium (Spiriva) Respimat for the treatment of asthma in adults aged 18 years and over. The MAA is based on results ...
-
Boehringer Ingelheim Has Obtained Marketing Approval for Striverdi Respimat
Oct 23, 2013Boehringer Ingelheim has obtained marketing approval for Striverdi Respimat (olodaterol), a long-lasting bronchodilator indicated for chronic obstructive pulmonary disease (COPD), in the UK, Denmark and Iceland. This approval is based ...
-
Boehringer Ingelheim Has Selected Certara's D360 as Its Global Drug Discovery Platform
Oct 21, 2013German pharmaceutical firm Boehringer Ingelheim has selected Certara's D360 as its global drug discovery platform, which will help in sharing discovery data across global working groups that can include external collaborators. Certara is ...
-
Boehringer Ingelheim Has Submitted a Marketing Authorisation Application to EMA
Oct 16, 2013Boehringer Ingelheim has submitted a marketing authorisation application to the European Medicines Agency (EMA) for the approval of its oral triple angiokinase inhibitor nintedanib. Nintedanib to be used in combination with docetaxel is ...
Tags: Boehringer Ingelheim, Lung Cancer
-
Companion Diagnostic Tests Was Developed by Ventana Partners and Bi for Cancer Drugs
Sep 19, 2013Ventana Medical Systems,a member of the Roche Group, and pharmaceutical company Boehringer Ingelheim (BI) have entered into a collaboration agreement for the development of companion diagnostic tests for BI oncology programs. Companion ...
-
FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC
Jul 16, 2013The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
-
EMA Accepted Eli Lilly and Boehringer Ingelheim's MAA for a Glargine Product
Jul 10, 2013The European Medicines Agency (EMA) has accepted Eli Lilly and Company and Boehringer Ingelheim's marketing authorisation application (MAA) for a new insulin glargine product, LY2963016, for review. The application has been filed through ...
